Throughout the last three months, 4 analysts have evaluated Editas Medicine (NASDAQ:EDIT), offering a diverse set of opinions from bullish to bearish. The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months. Analysts have recently evaluated Editas Medicine and provided 12-month price targets. The average target is $11.75, accompanied by a high estimate of $15.00 and a low estimate of $7.00. Experiencing a 16.07% decline, the current average is now lower than the previous average…